Robert Waltermire E.'s Insider Trades & SAST Disclosures
Robert Waltermire E.'s most recent trade in Madrigal Pharmaceuticals Inc was a trade of 7,288 Common Stock done at an average price of $87.1 . Disclosure was reported to the exchange on March 5, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert Waltermire E..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.09 per share. | 05 Mar 2025 | 7,288 | 17,841 (0%) | 0% | 87.1 | 634,712 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 7,288 | 3,062 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 05 Mar 2025 | 6,825 | 10,553 (0%) | 0% | 87.9 | 600,054 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 6,825 | 4,375 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 343.85 per share. | 05 Mar 2025 | 4,701 | 5,140 (0%) | 0% | 343.8 | 1,616,429 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 2,061 | 5,789 (0%) | 0% | 0 | Common Stock | |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 336.78 per share. | 05 Mar 2025 | 1,777 | 15,164 (0%) | 0% | 336.8 | 598,457 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 340.75 per share. | 05 Mar 2025 | 1,657 | 11,961 (0%) | 0% | 340.8 | 564,627 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 344.76 per share. | 05 Mar 2025 | 1,412 | 3,728 (0%) | 0% | 344.8 | 486,797 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 1,157 | 1,157 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 338.09 per share. | 05 Mar 2025 | 1,146 | 14,018 (0%) | 0% | 338.1 | 387,452 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 342.90 per share. | 05 Mar 2025 | 1,077 | 9,841 (0%) | 0% | 342.9 | 369,300 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 341.84 per share. | 05 Mar 2025 | 1,043 | 10,918 (0%) | 0% | 341.8 | 356,537 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 335.15 per share. | 05 Mar 2025 | 900 | 16,941 (0%) | 0% | 335.1 | 301,631 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 339.68 per share. | 05 Mar 2025 | 400 | 13,618 (0%) | 0% | 339.7 | 135,874 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 340.99 per share. | 28 Feb 2025 | 1,052 | 3,903 (0%) | 0% | 341.0 | 358,717 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 341.55 per share. | 28 Feb 2025 | 175 | 3,728 (0%) | 0% | 341.5 | 59,771 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 335.24 per share. | 24 Jan 2025 | 103 | 4,955 (0%) | 0% | 335.2 | 34,530 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 273.41 per share. | 17 Jan 2025 | 442 | 5,058 (0%) | 0% | 273.4 | 120,847 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 1,900 | 10,350 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.09 per share. | 14 Jun 2024 | 1,900 | 7,400 (0%) | 0% | 87.1 | 165,471 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 280.00 per share. | 14 Jun 2024 | 1,900 | 5,500 (0%) | 0% | 280 | 532,000 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 2,000 | 15,200 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 285.00 per share. | 12 Jun 2024 | 2,000 | 5,500 (0%) | 0% | 285 | 570,000 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 12 Jun 2024 | 2,000 | 7,500 (0%) | 0% | 87.9 | 175,840 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 231.34 per share. | 21 May 2024 | 1,036 | 5,500 (0%) | 0% | 231.3 | 239,668 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 2,138 | 2,138 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Waltermire E. Robert | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 1,419 | 1,419 | - | - | Market Stock Unit | |
| Madrigal Pharmaceuticals Inc | Waltermire E. Robert | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 1,419 | 6,536 (0%) | 0% | 0 | Common Stock | |
| Madrigal Pharmaceuticals Inc | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.92 per share. | 16 Jan 2024 | 550 | 5,117 (0%) | 0% | 243.9 | 134,156 | Common Stock |
| Madrigal Pharmaceuticals Inc | E. Waltermire Robert | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 2,000 | 19,200 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 14 Dec 2023 | 2,000 | 7,667 (0%) | 0% | 87.9 | 175,840 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 2,000 | 17,200 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | E. Waltermire Robert | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 14 Dec 2023 | 2,000 | 7,667 (0%) | 0% | 87.9 | 175,840 | Common Stock |
| Madrigal Pharmaceuticals Inc | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 236.00 per share. | 14 Dec 2023 | 1,000 | 6,667 (0%) | 0% | 236 | 236,000 | Common Stock |
| Madrigal Pharmaceuticals Inc | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 232.00 per share. | 14 Dec 2023 | 1,000 | 5,667 (0%) | 0% | 232 | 232,000 | Common Stock |
| Madrigal Pharmaceuticals Inc | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 241.00 per share. | 14 Dec 2023 | 1,000 | 5,667 (0%) | 0% | 241 | 241,000 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert Waltermire E. | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 233.00 per share. | 14 Dec 2023 | 1,000 | 6,667 (0%) | 0% | 233 | 233,000 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 12 Dec 2023 | 2,500 | 8,167 (0%) | 0% | 87.9 | 219,800 | Common Stock |
| Madrigal Pharmaceuticals Inc | E. Robert Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2023 | 2,500 | 21,200 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | E. Waltermire Robert | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 225.00 per share. | 12 Dec 2023 | 1,500 | 6,667 (0%) | 0% | 225 | 337,500 | Common Stock |
| Madrigal Pharmaceuticals Inc | Waltermire E. Robert | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2023 | 1,300 | 23,700 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | E. Waltermire Robert | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 12 Dec 2023 | 1,300 | 6,967 (0%) | 0% | 87.9 | 114,296 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert Waltermire E. | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 226.00 per share. | 12 Dec 2023 | 1,000 | 5,667 (0%) | 0% | 226 | 226,000 | Common Stock |
| Madrigal Pharmaceuticals Inc | Waltermire E. Robert | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 219.00 per share. | 12 Dec 2023 | 800 | 5,667 (0%) | 0% | 219 | 175,200 | Common Stock |
| Madrigal Pharmaceuticals Inc | E. Robert Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 216.00 per share. | 12 Dec 2023 | 500 | 6,467 (0%) | 0% | 216 | 108,000 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 28 Feb 2023 | 5,000 | 10,667 (0%) | 0% | 87.9 | 439,600 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 5,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 5,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 28 Feb 2023 | 5,000 | 10,667 (0%) | 0% | 87.9 | 439,600 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 272.30 per share. | 28 Feb 2023 | 4,100 | 5,667 (0%) | 0% | 272.3 | 1,116,430 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 273.44 per share. | 28 Feb 2023 | 1,928 | 8,739 (0%) | 0% | 273.4 | 527,192 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 274.57 per share. | 28 Feb 2023 | 1,672 | 7,067 (0%) | 0% | 274.6 | 459,081 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 275.53 per share. | 28 Feb 2023 | 1,300 | 5,767 (0%) | 0% | 275.5 | 358,189 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 271.03 per share. | 28 Feb 2023 | 900 | 9,767 (0%) | 0% | 271.0 | 243,927 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 276.19 per share. | 28 Feb 2023 | 100 | 5,667 (0%) | 0% | 276.2 | 27,619 | Common Stock |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 5,667 | 5,667 (0%) | 0% | 0 | Common Stock | |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 12,250 | 12,250 | - | - | Call Option | |
| Madrigal Pharmaceuticals Inc | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 35,000 | 35,000 | - | - | Call Option |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges